The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors.
Hendrik-Tobias Arkenau
No relevant relationships to disclose
Suzanne Fields Jones
No relevant relationships to disclose
Carla Kurkjian
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
Shubham Pant
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Kathleen N. Moore
No relevant relationships to disclose
D. Scott McMeekin
No relevant relationships to disclose
Frank A. Greco
No relevant relationships to disclose
Sara Ramsey
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose